The FDA approved the PI3K/AKT/mTOR inhibitor Revtorpyk with fulvestrant and with or without Pfizer's CDK4/6 Ibrance based on Phase III data.

The above video aired in a previous newscast. NEW YORK CITY (PIX11) — It’s been a week since two columns buckled at the ...

Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very ...

Learn more A high-yielding dividend may sound great for investors, but it can be a double-edged sword: when it's too high, ...

Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its ...

Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts ...

Developer MetroLoft closed on another office building just days before a structural failure halted construction at its project on East 42nd Street.

Even as the effort has met with fierce pushback from drugmakers, trade groups and opposition parties in the country’s own ...

Realty Income generates monthly property income; its 5.1% yield and track record of dividend growth point to steady total ...

Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

The 37-story Pfizer building in midtown was stabilized, after almost falling over earlier this week. Now the real-estate ...

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes ...